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Abstract 
Stem cell treatments are a desirable therapeutic option to regenerate myocardium and improve cardiac function after 
myocardial infarction. Several different types of cells have been explored, each with their own benefits and limitations. 
Induced pluripotent stem cells possess an embryonic-like state and therefore have a high proliferative capacity, but 
they also pose a risk of teratoma formation. Mesenchymal stem cells have been investigated from both bone marrow 
and adipose tissue. Their immunomodulatory characteristics may permit the use of allogeneic cells as universal donor 
cells in the future. Lastly, studies have consistently shown that cardiac stem cells are better able to express markers of 
cardiogenesis compared to other cell types, as well improve cardiac function. The ideal source of stem cells depends 
on multiple factors such as the ease of extraction/isolation, effectiveness of engraftment, ability to differentiate into 
cardiac lineages and effect on cardiac function. Although multiple studies highlight the benefits and limitations of 
each cell type and reinforce the successful potential use of these cells to regenerate damaged myocardium, more 
studies are needed to directly compare cells from various sources. It is interesting to note that research using stem cell 
therapies is also expanding to treat other cardiovascular diseases including non-ischemic cardiomyopathies.
Keywords: Myocardial infarction, Induced pluripotent stem cells, Mesenchymal stem cells, Cardiac stem cells,  
Stem cell therapy, Bone marrow, Adipose tissue
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Introduction
Myocardial infarction (MI) is a leading cause of mor-
bidity and mortality worldwide [1]. MI occurring from 
coronary artery disease can cause reversible or irrevers-
ible ischemic damage, depending on the reperfusion sta-
tus afterwards. This ischemic damage results in the loss 
of cardiomyocytes due to apoptosis [2]. Following the 
formation of necrotic myocardium, a secondary inflam-
matory immune response occurs as myofibroblasts are 
recruited to the area resulting in scar formation and 
reduced ventricular function [3].
Current options to re-perfuse occluded arteries include 
medical, percutaneous coronary intervention and surgi-
cal strategies, which have significantly improved out-
comes after MI [4]. However, these techniques do not 
reverse necrotic or ischemic myocardium. Research 
is now focusing on techniques to regenerate damaged 
myocardium to regain heart function, one of which is the 
use of stem cells.
Studies are currently investigating a number of differ-
ent cell types including embryonic, induced pluripo-
tent, mesenchymal and cardiac derived stem cells. There 
are many considerations to be taken into account when 
selecting an ideal cell type. For example, in order to 
improve heart function, cells must be able to differenti-
ate into myocytes, vascular endothelial cells and smooth 
muscle cells or must act via paracrine mechanisms. Their 
extraction and isolation must be feasible and transplan-
tation into humans must be safe and effective. In the 
following review, different cell types will be discussed 
in terms of the benefits and limitations of each type 
(Table 1).
Results
Embryonic/induced pluripotent stem cells
Embryonic stem cells can give rise to all cell types found in 
an organism. They are derived from the inner cell mass of 
the blastocyst during mammalian embryonic development 
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[5]. However, there are several ethical and political issues 
surrounding the use of embryonic stem cells as well as a lim-
ited supply of donor human embryos. This led to the devel-
opment of induced pluripotent stem cells (iPSs). IPss were 
first reprogrammed from adult mouse fibroblasts by the 
presence of certain factors, including Oct ¾, Sox2, c-Myc 
and Klf4 in culture. These iPSs successfully demonstrated 
an embryonic-like state, exhibiting growth properties and 
specific marker genes of embryonic cells [6, 7]. Shortly later, 
human iPSs, capable of differentiating into cell types from 
all three germ layers, were reprogrammed from human 
fibroblasts using the same four factors [8, 9]. Research has 
continued to focus on optimizing techniques used to form 
human iPSs such as using different factors and culture con-
ditions. For example, human iPSs were generated using 
Oct4, Sox2, Nanog and Lin28 transgenes [10, 11].
For clinical application, these human induced pluripo-
tent stem cells (hiPSs) must be able to differentiate into 
functional cardiomyocytes or cardiac progenitors. There 
is a large body of research regarding various differen-
tiation techniques. One research group made use of the 
transcription factors used to induce pluripotency to also 
encourage differentiation into cardiac lineages. Oct ¾ is a 
transcription organizer that plays a gatekeeper role in the 
pluripotency of embryonic stem cells by interacting with 
the Sox2 promoter. Once this is achieved, Oct ¾ inter-
acts with the Sox17 promoter to signal cardiogenesis [12]. 
Another research group used the addition of particular 
growth factors, including BMP and GSK3, to direct differ-
entiation into cardiac progenitor cells [13]. Cardiac differ-
entiation was confirmed using an embryoid body protocol 
by electrophysiology studies that verified the formation of 
nodal, atrial and ventricular-type cardiac cells from these 
cells [10]. These studies confirm the ability for iPSs to dif-
ferentiate into cardiac lineages, thus making them good 
candidates for the treatment of cardiovascular disease.
In order to evaluate the effect of these cells on heart 
function, differentiated cardiac cells then must be trans-
planted into hearts. Injection of iPSs into rat myocardium 
resulted in successful engraftment and differentiation 
into cardiomyocytes, vascular endothelium and smooth 
muscle cells along with an increased ejection fraction and 
decreased fibrosis [14, 15]. In a porcine model, hiPSC-
derived cardiomyocytes, endothelial cells and smooth 
muscle cells were integrated into host myocardium using 
an intramyocardial microsphere transplantation tech-
nique. This resulted in improved LV function, myocardial 
metabolism and reduced infarct size [16]. In a larger ani-
mal model, cardiac committed ESCs were transplanted 
into infarcted sheep hearts. Results demonstrated suc-
cessful engraftment and preservation of ejection fraction 
[17]. Overall, these in vivo studies demonstrate a positive 
effect of implanted cells on cardiac function.
Although studies mentioned above demonstrate suc-
cessful use and effect on cardiac function of iPSs in animal 
studies, progress is still needed in clinical trials. Clinical tri-
als have not yet been initiated for iPSs use for the treatment 
of myocardial infarction. Before this can be done, there is a 
need to establish a reproducible and more standardized dif-
ferentiation technique. In terms of embryonic stem cells, the 
first clinical trial was recently initiated in Paris. A phase 1 
clinical trial, ESCORT, is currently examining the effect of 
embryonic stem cell derived progenitors on severe heart 
failure. These cells are driven towards a cardiac fate before 
Table 1 Summary of  advantages, disadvantages and  current clinical trials for  the various sources of  stem cells men-
tioned in this article
iPSs induced pluripotent stem cells; MSCs mesenchymal stem cells; CSCs cardiac stem cells
Cell type Advantages Disadvantages Current clinical trials
Embryonic stem cells Effectively differentiate into all three primary germ 
layers
Ethical/political issues surrounding the use of 
these cells
ESCORT
iPSs Demonstrate an embryonic-like state and can be 
derived from somatic cells
Strong regenerative capacity and integration 
within host cardiomyocytes
Risk of teratoma formation, thus there is a need to 
direct differentiation before transplantation
None
MSCs Immunomodulatory characteristics permits the 
potential to use allogeneic cells
Self-renewal, proliferation and differentiation 
properties
More studies needed to support the efficacy of 
these cells on a long-term basis
BOOST, REPAIR-AMI,
 Bone marrow Immunomodulatory characteristics
Easy to isolate via liposuction
Rich source of stem cells
MySTromalCell Trial
The Precise Trial Adipose tissue
CSCs Express cardiac specific markers and can thus dif-
ferentiate more effectively into cardiomyocytes 
compared to other cell types
Difficult to isolate/extract cells
Need for ex vivo expansion before transplantation, 
which can be costly
SCIPIO, CADUCEUS
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transplantation and are embedded into a fibrin gel before 
being administered via epicardial delivery to patients under-
going coronary artery bypass grafting (CABG) or a mitral 
valve procedure. The first clinical case report using embry-
onic stem cell derived cardiac progenitor cells was recently 
published and demonstrated symptomatic improvement 
and echocardiographically evident new contractility with an 
LVEF improving from 26 % to 36 % after 3 months [18].
Induced pluripotent stem cells are attractive because of 
their ability to differentiate into large numbers of cardio-
myocytes. There is better functional integration within 
host heart cells in comparison to adult cells, specifically 
in terms of the electromechanical connections with host 
cardiomyocytes. A limitation to the use of these cells is 
the associated risk of teratoma formation after trans-
plantation of undifferentiated cells into infarcted hearts. 
In one study, the transplantation of undifferentiated syn-
genic iPSs into mice resulted in teratoma formation in 
65 % of transplantation sites after 30 days [19, 20]. This 
result emphasizes the need for a method to control or 
direct differentiation of iPS towards cardiac progenitor 
cells before transplantation to avoid the formation of ter-
atomas or alternate and undesired cell types [21]. Overall, 
additional animal studies are needed to ensure the safety 
and efficacy of these cells.
Mesenchymal stem cells
Mesenchymal stem cells (MSCs) can be found in bone 
marrow, adipose tissue, umbilical cord blood and pla-
centa. They are capable of differentiating into lineages 
such as osteocytes, chondrocytes, adipocytes, myocytes 
and marrow stroma [22]. These cells are hypothesized to 
secrete soluble growth factors and cytokines that act in 
endocrine and paracrine fashions, contributing to their 
therapeutic effect [23].
MSCs are advantageous due to their immunomodula-
tory characteristics, which allow them to act as a univer-
sal reserve of donor cells (Fig. 1) [24]. These cells have a 
unique distribution of surface markers that allows them 
to escape detection from immune cells. Specifically, they 
possess decreased levels of MHC class I and costimula-
tory CD40, CD80 and CD86, with no MHC class II mol-
ecules [25, 26].
Despite low cellular retention and poor differentiation 
into cardiomyocytes, studies were still demonstrating 
improved heart function [27], which suggests a potential 
paracrine mechanism of action for transplanted MSCs. 
MSCs release angiogenic, apoptotic, mitogenic and hom-
ing factors that have cardio-protective actions [28]. Spe-
cifically, a recent study demonstrated the importance 
of hepatocyte growth factor (HGF) in angiogenesis and 
proliferation of cardiomyocytes [29]. Furthermore, trans-
plantation of MSCs indirectly stimulated endogenous 
cardiac progenitor cells through a paracrine mechanism. 
Released factors such as HGF, VEGF and IGF-1 triggered 
activation, proliferation, and migration of resident car-
diac progenitors. Specifically, they inhibited apoptosis 
of cardiac progenitors and upregulated the expression of 
cardiomyocyte related genes in order to direct differen-
tiation [30].
Results from studies using MSCs derived from bone 
marrow and adipose tissue will be discussed below.
Fig. 1 Suggested pathways underlying the immunomodulatory properties of mesenchymal stem cells This figure is adapted from [24]
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Bone marrow
Injury to an organ triggers stem cells from distant sites to 
migrate to the area of damage, where they can differen-
tiate and help repair the damaged organ. This reparative 
effect had been demonstrated in muscle, liver and brain 
tissues [31–33]. In 2001, Orlic et al. investigated whether 
stem cells from a distant site directly transplanted into 
the heart could regenerate scarred areas. Results dem-
onstrated that locally delivered autologous bone mar-
row stem cells could regenerate damaged myocardium 
in infarcted mice hearts [34]. This finding led to further 
research examining the differentiation of MSCs into car-
diac lineages and the specific effects on cardiac function.
For example, in vitro MSCs were capable of differenti-
ating into cardiomyocytes, as demonstrated when MSCs 
were co-cultured with neonatal ventricular myocytes 
[35]. In animal models, MSCs derived from bone mar-
row injected into mice and rat hearts post MI showed 
successful engraftment and differentiation into cardio-
myogenic and vascular phenotypes [36–38]. It has also 
been found that the hypoxic environment of infarction 
may induce the expression of certain factors (vascular 
endothelial growth factor, myocardin, insulin like growth 
factor) which can promote the differentiation of MSCs to 
cardiomyocytes [39, 40]. Percutaneous transendocardial 
injection of bone marrow derived MSCs into pig hearts 
post-MI showed an improved ejection fraction after 
4 weeks, in comparison to bone marrow derived mono-
nuclear cells [41].
The above studies all used MSCs derived from autolo-
gous sources. However, as mentioned, an advantage of 
MSC is their immunomodulatory characteristics. This 
led to numerous studies comparing results from alloge-
neic vs autologous cells. In vitro, MSCs co-cultured with 
immune cells upregulated the secretion of suppressive 
cytokines (i.e. IL-4 and IL-10), decreasing the secretion 
of proinflammatory cytokines (TNF-α and IFN-ɣ) from 
dendritic cells, T helper cells and macrophages [42]. 
Soluble mediators including prostaglandin E2 are impor-
tant for this immunosuppression [43]. In  vivo, direct 
intramyocardial injection of bone marrow derived MSCs 
1  month after MI in a porcine model resulted in pre-
served left ventricular ejection fraction at 60 and 90 days 
post MI in comparison with the untreated subjects [44]. 
Similarly, global left ventricular ejection fraction (LVEF) 
improved along with a decrease in infarct size by 40 % in 
sheep treated with intracoronary infusion of allogeneic 
bone marrow derived MSCs in comparison to untreated 
sheep [45]. With this being said, there is a lack of evi-
dence supporting the benefit of these cells on a long-term 
basis. For example, intramyocardial injection of MSCs 
resulted in an initial improvement in cardiac function. 
This effect was no longer observed after 1  month, and 
there was noted immune cell infiltration and subsequent 
rejection of MSCs [46]. Preliminary results demonstrate 
benefit from the use of allogeneic MSCs. Future studies 
that focus on enhancing the long term efficacy of these 
treatments could permit the use of cells from young 
healthy donors, eliminating the need for MHC matching 
prior to treatment.
There have been numerous clinical trials evaluating 
the effect of MSCs in humans with cardiovascular dis-
ease. The BOOST trial involved intracoronary admin-
istration of autologous bone marrow derived MSCs in 
patients who received percutaneous coronary interven-
tion for acute STEMI’s. After 6 months, the global LVEF 
increased by 6.7  % in the treated group vs 0.7  % in the 
control group [47]. Another trial in 2006 assessed cardiac 
function after intracoronary administration of autolo-
gous bone marrow derived MSCs 3–7  days post-MI. 
After 4 months the LVEF increased by 5.5 % in the treated 
group vs 3 % in the control group [48]. A phase I trial ini-
tiated in 2009 evaluated the safety and efficacy of bone 
marrow derived allogeneic MSCs (Prochymal) delivered 
intravenously to patients post-MI. Results demonstrated 
better global symptom scores and ejection fractions in 
patients receiving MSC’s compared to the control group. 
Improvements in LVEF were also seen on cardiac MRI in 
the group treated with MSCs [49].
Adipose tissue
MSCs can also be isolated from adipose tissue, specifi-
cally the stromal fraction of adipose tissue. These cells are 
attractive due to the ease of extraction using liposuction. 
Adipose tissue is also considered a richer source of pro-
genitors compared to bone marrow, containing 100–500 
times the amount [50].
In animal models, adipose tissue derived MSCs 
injected into rat myocardium post-MI resulted in an 
improved LVEF compared to untreated rats [51], as well 
as reduced fibrosis and less wall thinning [52]. More 
recently, adipose tissue derived stem cells were used 
to create cardiac-like progenitors (iCPs). Adipose tis-
sue derived stem cells, induced cardiac progenitors and 
bone marrow derived stem cells were delivered into mice 
hearts post-MI. At 1 month post-transplant, mice trans-
planted with iCPs and adipose derived stem cells showed 
higher myocardial capillary densities. All three samples 
showed a decrease in infarct size compared to the control 
or untreated sample; however the greatest reduction was 
seen in those transplanted with iCPs, which were derived 
from adipose tissue stem cells [53].
Similar to bone marrow MSCs, those derived from 
adipose tissue also possess immunomodulatory proper-
ties. In vitro, MSCs derived from adipose tissue showed 
greater immunosuppressive effects when cultured with 
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immune cells than MSCs derived from bone marrow or 
umbilical cord matrix. Specifically, they showed a greater 
inhibitory effect on CD4+  and CD8+  T cell activation 
and natural killer cell activation. They also displayed a 
suppressive effect on B cells [54]. In a separate study, adi-
pose tissue MSCs were found to inhibit B cell function 
more effectively than bone marrow derived cells [55]. 
These studies indicate the effective immunosuppressive 
characteristics of MSCs derived from adipose tissue, sup-
porting their use as a future therapeutic agent.
The mesenchymal stromal cell therapy in patients with 
chronic myocardial ischemia (MyStromalCell Trial) is 
a phase II study using adipose derived cells, stimulated 
with VEGF-A165, to determine the effect on patients with 
chronic ischemic heart disease and refractory angina 
[56]. The Precise Trial is using adipose tissue derived cells 
for transendocardial injections in patients with ischemic 
cardiomyopathy. Preliminary results show improvements 
in left ventricular mass and motion score index in treated 
patients after 18 months [57].
These cells continue to be attractive due to their ease 
of isolation via liposuction and their immunosuppressive 
qualities.
Cardiac stem cells
Until recently, it was believed that myocytes were inca-
pable of regeneration; however, evidence suggests that 
myocytes can mitotically divide post MI [58]. The same 
author studied a subpopulation of cells found within the 
heart, and proved that they hold properties of cardiac 
stem cells, with the potential to give rise to myocytes, 
smooth muscle and endothelial cells [59]. These cells 
were found to express markers of both mesenchymal 
stem cells (CD90, CD105), embryonic stem cells (Rex1, 
Nanog, Sox2) and also early markers of cardiogenesis 
(platelet derived growth factor receptor-α) [60, 61]. There 
are multiple different types of cardiac stem cells (CSCs) 
including ckit+  cells, Isl 1+  cells, cardiac mesoangio-
blasts, cardiosphere derived cells and epicardial progeni-
tors which all express slightly different but overlapping 
surface markers [3].
Cardiac stromal cells can be isolated from adult human 
auricles. These cells expressed cardiovascular markers 
more efficiently than bone marrow MSCs in vitro. In vivo, 
cells originating from cardiac tissue differentiated more 
effectively into cardiomyocytes when injected into rat 
myocardium post MI [62]. Another study compared the 
effects of adipose tissue derived stem cells from subcu-
taneous vs pericardial origin. The cells from a pericardial 
origin showed better expression of intrinsic transcription 
factors for cardiogenesis. After administration of cells to 
infarcted hearts, they demonstrated increased vasculo-
genesis and myogenesis as well as more effective overall 
reparative activity [63]. Animal studies consistently dem-
onstrate that cardiac stem cells possess a greater ability to 
differentiate into cells of cardiac lineages and can more 
efficiently obtain structural characteristics of myocytes 
and vessels [64]. Therefore, they are an attractive option 
for future therapeutics for cardiovascular disease.
Several studies have focused on the use of cardiosphere 
derived stem cells for treatment post-MI. To generate 
these cells, percutaneous endomyocardial biopsied cells 
are grown in culture to form cardiospheres which are 
then expanded ex vivo to generate cardiosphere derived 
cells before transplantation. Human and porcine car-
diosphere derived cells successfully expressed antigenic 
characteristics of stem cells. In animal studies, injec-
tions of human derived cells into infarcted myocardium 
resulted in improved LVEF in mice [65] and the forma-
tion of new cardiac tissue and a reduction in infarct 
size in porcine [66]. A challenge associated with the use 
of cardiac stem cells is harvesting technique. In most 
studies, autologous cardiac stem cells are isolated from 
atrial appendages, ventricles or epicardial biopsies and 
are expanded in culture before use [67]. This method is 
advantageous because it provides a feasible technique to 
generate a larger number of cardiac stem cells from very 
small biopsies.
Clinical trials have already begun. The stem cell infu-
sion in patients with ischemic cardiomyopathy (SCIPIO) 
is a phase I clinical trial administering autologous car-
diac stem cells to patients with heart failure undergo-
ing CABG. Preliminary results demonstrate an increase 
in LVEF at 4 and 12  months after infusion as well as a 
decrease in infarct size [68]. The Intracoronary cardio-
sphere-derived cells for heart regeneration after myo-
cardial infarction (CADUCEUS) trial is a phase 1 study 
examining the use of autologous cells grown from per-
cutaneous endomyocardial biopsies. MRI results after 
6  months showed reductions in scar mass, increases in 
viable heart mass and contractility in the treated group 
[69].
An obstacle to the use of cardiac stem cells would be 
the fact that they need to be expanded ex  vivo before 
transplantation, which can be costly [70]. Non-specific 
differentiation into other lineages such as adipocytes and 
skeletal muscle has been observed on occasion [71, 72]. 
Some techniques are focusing on activating endogenous 
cardiac stem cell pools using growth factors, microR-
NAs or drugs rather than actually transplanting cells. For 
example, one study identified a hepatocyte growth factor 
and insulin growth like factor receptor system in cardiac 
stem cells. Infarcted dog hearts were injected with these 
factors, resulting in the formation of new myocytes and 
coronary vessels in the infarcted region, with expressed 
proteins specific for cardiomyocytes [73]. This method 
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would avoid complications associated with ex  vivo 
expansion of cells.
Despite the challenges, studies have consistently dem-
onstrated that cardiac stem cells possess the ability to 
more efficiently differentiate into cardiomyocytes and 
vascular endothelial cells as well as improve cardiac func-
tion [74]. There is also potential for expansion to treat a 
variety of cardiovascular diseases. For example, a study 
in 2014 even demonstrated the capability of CSCs iso-
lated from mouse hearts to differentiate into sinus node 
like cells when co-cultured with mouse sinus node tissue 
[75]. This would have potential clinical applications for 
the treatment of sick sinus syndrome. More studies are 
needed to determine the feasibility of using cardiac stem 
cells.
Conclusion
Myocardial infarction is a leading cause of death world-
wide. The use of stem cells to regenerate damaged myo-
cardium and restore function continues to be a potential 
therapeutic option. Several different types of stem cells 
have been investigated for this purpose. Ideal stem cells 
must be capable of differentiating into cardiomyocytes 
and vascular endothelial cells. They must be able to suc-
cessfully engraft and integrate within the host myo-
cardium, mechanically and electrically [67] or provide 
benefit via paracrine mechanisms [30]. It is important 
that the source of cells demonstrates cardiogenic poten-
tial. Another consideration is the ease of isolation.
There are ethical issues regarding the use of embry-
onic stem cells. However, induced pluripotent stem cells 
formed from fully differentiated somatic cells were found 
to possess an embryonic-like state. These cells have the 
ability to easily differentiate into large numbers of cardio-
myocytes [14]. However, the use of proliferative undif-
ferentiated pluripotent cells carries the risk of teratoma 
formation. Therefore, it is essential to differentiate the 
cells into cardiac lineages prior to transplantation.
Mesenchymal stem cells can be isolated from several 
sources including bone marrow and adipose tissue. Both 
sources have demonstrated successful differentiation into 
cardiac lineages as well as positive impacts on cardiac 
function in animal models. An advantage of mesenchy-
mal stem cells is their immunomodulatory properties. It 
has been shown that there is a limited capacity for pro-
liferation in cells from aged individuals who may or may 
not have additional comorbidities [76]. This would per-
mit the use of allogeneic stem cells from young healthy 
donors for elderly patients to treat acute MI.
Studies have consistently demonstrated that cardiac 
stem cells possess the ability to more efficiently differen-
tiate into cardiomyocytes and vascular endothelial cells 
as well as improve cardiac function. However, these cells 
may be more difficult to obtain compared to the other 
cell types. In one study, cardiac stem cells were isolated 
via endomyocardial biopsies of explanted hearts or at 
the time of left ventricular assist device implantation. 
This research showed that growth characteristics of cells 
taken from small endomyocardial biopsies (5 mg in size) 
in patients with heart failure were comparable to those 
from larger biopsies [77]. Although these samples are 
more difficult to obtain, studies are focusing on the use 
of expansion ex vivo before transplantation into damaged 
hearts.
Overall, this research offers a new method to treat 
myocardial infarction. Each cell type has its own ben-
efits and limitations but more studies that directly com-
pare the effectiveness of each cell type are warranted. 
Initially, studies focused on regeneration of myocardium 
for ischemic heart disease; however, studies are now 
expanding to include a larger spectrum of cardiovascular 
diseases.
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